The expanding role of pharmacy and therapeutics committees. The 1990s and beyond

PharmacoEconomics

Volumn 10, Issue 2, 1996, Pages 123-128

  Wade, William E ^a   Spruill, William J ^a   Taylor, A Thomas ^b   Longe, R Leon ^b   Hawkins, David W ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; PHARMACY; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 0029743666     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199610020-00004     Document Type: Review

References (36)

1. American Society of Hospital Pharmacists. Lilly survey shows sharp increase in hospital pharmacies' purchases. Am J Hosp Pharm 1992; 49: 745-6
2. American Society of Hospital Pharmacists (ASHP). Practice standards of ASHP 1991-1992. Bethesda (MD): American Society of Hospital Pharmacists, 1991
3. Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including major submissions involving economic analyses. Canberra: Australian Government Publishing Service, 1995
4. Nash DB, Catalano ML, Wordell CJ. The formulary decision-making process in a US academic medical centre. Pharmaco-Economics 1993; 3 (1): 22-35
5. Joint Commission on Accreditation of Hospitals (JCAH). Accreditation manual for hospitals. Chicago: JCAH, 1965
6. Lipman AC. A new formulary statement and formulary service [editorial]. Hosp Formul 1983; 18: 771
7. Hunter WJ, Davis RB. Formulary review and DUE of oral ketorolac. P&T 1994 Oct; 19: 953, 957-8, 962, 965
8. Taylor G, Blondel-Hill E, Kibsey P, et al. Containing cefoxitin costs through a program to curtail use in surgical prophylaxis. Can J Infect Dis 1993; 4: 275-8
9. Cimino MA, Rotstein CM, Moser JM. Assessment of cost-effective antibiotic therapy in the management of infections in cancer patients. Ann Pharmacother 1994; 28: 105-11
10. Moody SB, Sveska KJ. Fluconazole dosing in renal impairment: a drug usage evaluation. Hosp Formul 1993; 28: 499-502
11. Hayman JN, Crane VS. Multi disciplinary task force for controlling drug expenses. Am J Hosp Pharm 1993; 50: 2343-7
12. Schlicht JR, Porter CK, Weber DR, et al. Drug use evaluations of intravenous ciprofloxacin: changing prescribing practices through education. P&T 1994 Dec; 19: 1120, 1123-4, 1126-7
13. Wade WE, McCall CY. Educational effort and CQI program improves ordering of serum digoxin levels. Hosp Formul 1994; 29: 657-9
14. Successful conversion from lovastatin to pravastatin in a staff model HMO. Hosp Formul 1994; 29: 104-5
15. Wade WE, McCall CY. How a CQI program improved amino-glycoside use in a community hospital. Hosp Formul 1995; 30: 114-6
16. Matanin D, Cutrell D. A continuous quality improvement program for phenytoin IV. Hosp Formul 1994; 29: 212-5
17. Gianarkis DG. Ketorolac formulary restriction and usage evaluation [letter]. Drug Intell Clin Pharm 1991; 25: 1399
18. Drexler PG, Lambdin CS. Reducing outpatient costs of non-steroidal antiinflammatory drugs at a department of veterans affairs teaching hospital. J Pharm Technol 1993; 9: 10-3
19. Okpara AU. Enforcing an antimicrobial restriction policy through amikacin DUE. P&T 1994 Apr; 19: 375-6, 379-83
20. Keith MR, Cason DM, Helling DK. Antiulcer prescribing program in a state correctional system. Ann Pharmacother 1994; 28: 792-5
21. Maswoswe JJ, Okpara A. Enforcing a policy for restricting antimicrobial drug use. Am J Health-System Pharm 1995; 52: 1433-5
22. Ament PW, Matanin D, Cutrell DK. Avoiding cost through pharmacy-managed interchange. P&T 1994 Sep; 19: 885-6, 891-2
23. Korman L, Borysiuk L. Replacing lovastatin with pravastatin: effect on serum lipids and costs. Am J Health-System Pharm 1995; 52: 1078-82
24. Frighetto L, Nickoloff D, Jewesson P. Antibiotic therapeutic interchange program: six years of experience. Hosp Formul 1995; 30: 92-3, 97-8, 100, 103-5
25. Ekedahl A, Petersson B, Eklund P, et al. Prescribing patterns and drug costs: effects of formulary recommendations and community pharmacist's information campaigns. Int J Pharm Pract 1994 Jun; 2: 194-9
26. Shepherd MD, Salzman RD. The formulary decision-making process in a health maintenance organisation setting. Pharmaco-Economics 1994; 5 (1): 29-38
27. Spilker B. Use and abuse of pharmacoeconomic trials. Drug News Perspect 1994; 7 (6): 363-9
28. Lee JT, Sanchez LA. Interpretation of cost-effective and soundness of economic evaluations in the pharmacy literature. Am J Hosp Pharm 1991; 48: 2622-7
29. Chase P, Bell J, Smith P, et al. Redesign of the P& T committee around continuous quality improvement principles. P&T 1995 Jan; 20: 25-6, 29-30, 32, 34, 37-8, 40
30. Jolicoeur LM, Jones-Grizzle AJ, Boyer JG. Guidelines for performing a pharmacoeconomic analysis. Am J Hosp Pharm 1992; 49: 1741-7
31. Sanchez LA. Pharmacoeconomic principles and methods: conducting pharmacoeconomic evaluations in a hospital setting. Hosp Pharm 1995; 30 (5): 412-28
32. Clemens K, Townsend R, Luscombe F, et al. Methodological and conduct principles for pharmacoeconomic research. PharmacoEconomics 1995; 8 (2): 169-74
33. Coons SJ, Kaplan RM. Quality of life assessment: understanding its use as an outcome measure. Hosp Formul 1993; 28: 486-98
34. Mackeigan LD, Palhak DS. Overview of health-related quality-of-life measures. Am J Hosp Pharm 1992; 49 (2): 236-45
35. Jaeschke R, Guyatt GH, Cook D. Quality of life instruments in the evaluation of new drugs. PharmacoEconomics 1992; 1: 84-93
36. Sanchez LA. Application of health-related quality of life to hospital pharmacy practice. Hosp Pharm 1995; 30 (10): 928-30